Hospital admissions for acute aortic dissection higher during flu season

17.12.20141536
Sandhu and colleagues conducted the study to compare national influenza activity from the CDC vs. monthly admissions for acute aortic dissection and their institution from 2001 to 2013.

The FDA today announced clearance of a new screening test that predicts a patient’s risk for future CHD events

16.12.20141602
The agency has cleared the test for use in all adults with no history of CHD.

Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial)

15.12.20141737
Patients undergoing catheter ablation for atrial fibrillation (AF) often experience recurrent arrhythmias within the first few months post-ablation.

Stroke and Major Bleeding Risk in Elderly Patients Aged ?75 Years With Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project

12.12.20141772
What are the risks of stroke and bleeding in elderly patients with atrial fibrillation (AF) associated with oral anticoagulation?

Opportunities for treatment optimization with beta-blockers, ivabradine often missed in HF clinic

11.12.20141550
Most HF patients with reduced ejection fraction treated at a community HF clinic received beta-blocker therapy to maintain a heart rate <70 bpm, but relatively few require beta-blocker up-titration or ivabradine initiation, results of a new study suggest.

Recent Cox-2 inhibitor use increased ischemic stroke mortality risk

10.12.20141358
The use of cyclooxygenase-2 inhibitors before hospitalization for stroke is associated with increased mortality in cases of ischemic stroke, but not hemorrhagic stroke, according to recent findings.

Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis

08.12.20141537
Experimental data indicate that reducing factor XI levels attenuates thrombosis without causing bleeding, but the role of factor XI in the prevention of postoperative venous thrombosis in humans is unknown. FXI-ASO (ISIS 416858) is a second-generation antisense oligonucleotide that specifically reduces factor XI levels.
Данный сайт и вся информация на нём предназначена для медицинских работников. Продолжая просмотр, вы соглашаетесь и подтверждаете, что являетесь медицинским работником.